NCT06998407 2026-02-20
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT07130643 2025-08-19
Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer
Hubei Cancer Hospital
Phase 2 Active not recruiting
NCT06860529 2025-06-23
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT05633914 2023-02-21
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
Hunan Cancer Hospital
Phase 2 Unknown